Mutations in the C-terminal region of the HIV-1 reverse transcriptase and their correlation with drug resistance associated mutations and antiviral treatment

European Journal of Medical Research

Volumn 15, Issue 10, 2010, Pages 415-421

  Michels, I ^a   Staszewski, S ^a   Gurtler L ^a   Nisius, G ^a   Muller A ^b   Locher, L ^c   Doerr, H W ^a   Stürmer, Martin ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Infektiologikum Frankfurt Sachsenhausen   (Germany)

^c Infektiologikum Frankfurt   (Germany)

Author keywords

Antiretroviral therapy; Connection domain; Genotypic resistance; Polymerase; Reverse transcriptase; RNase H

Indexed keywords

EMTRICITABINE; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PREVALENCE; VIRUS MUTATION;

EID: 78349299039     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-15-10-415     Document Type: Article

References (28)

1. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004 Mar 4; 350 (10): 1023-35.
2. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell. 1999 Jul; 4 (1): 35-43.
3. Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, Pathak VK. Mechanism for nucleoside analogmediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci U S A. 2005 Feb 8; 102 (6): 2093-8.
4. Sluis-Cremer N, Arion D, Parniak MA. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell Mol Life Sci. 2000 Sep; 57 (10): 1408-22.
5. Radzio J, Sluis-Cremer N. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol Pharmacol. 2008 Feb; 73 (2): 601-6. (Pubitemid 351159228)
6. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, Maldarelli F, Fivash MJ, Jr., Coffin JM, Pathak VK. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc Natl Acad Sci U S A. 2007 Jan 2; 104 (1): 317-22. (Pubitemid 46068029)
7. Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J Virol. 2007 Jul; 81 (13): 6837-45.
8. Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine. J Virol. 2007 Aug; 81 (15): 7852-9. (Pubitemid 47101471)
9. Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, Matsuoka M, Takiguchi M, Gatanaga H, Oka S. Amino Acid Mutation N348I in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Multi-class Resistance to Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitors. J Virol. 2008 Jan 23; 82 (7): 3261-70.
10. Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 2007 Dec; 4 (12): e335.
11. Roquebert B, Wirden M, Simon A, Deval J, Katlama C, Calvez V, Marcelin AG. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naive and pre-treated HIV infected patients. J Med Virol. 2007 Mar; 79 (3): 207-11. (Pubitemid 46213183)
12. Santos AF, Lengruber RB, Soares EA, Jere A, Sprinz E, Martinez AM, Silveira J, Sion FS, Pathak VK, Soares MA. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS ONE. 2008 3 (3): e1781.
13. Sturmer M, Berger A, Doerr HW. Modifications and substitutions of the RNA extraction module in the ViroSeq HIV-1 genotyping system version 2: effects on sensitivity and complexity of the assay. J Med Virol. 2003 Dec; 71 (4): 475-9. (Pubitemid 37309915)
14. Stürmer M, Berger A, Preiser W. HIV-1 genotyping: comparison of two commercially available assays. Expert Rev Mol Diagn. 2004 May; 4 (3): 281-91. (Pubitemid 38684705)
15. Sturmer M, Zimmermann K, Fritzsche C, Reisinger E, Doelken G, Berger A, Doerr HW, Eberle J, Gurtler LG. Regional spread of HIV-1 M subtype B in middle-aged patients by random env-C2V4 region sequencing. Med Microbiol Immunol. 2010 Mar; 199(2): 123-8.
16. Delviks-Frankenberry KA, Nikolenko GN, Boyer PL, Hughes SH, Coffin JM, Jere A, Pathak VK. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc Natl Acad Sci U S A. 2008 Aug 5; 105 (31): 10943-8.
17. Ntemgwa M, Wainberg MA, Oliveira M, Moisi D, Lalonde R, Micheli V, Brenner BG. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob Agents Chemother. 2007 Nov; 51 (11): 3861-9. (Pubitemid 350057782)
18. Ehteshami M, Beilhartz GL, Scarth BJ, Tchesnokov EP, McCormick S, Wynhoven B, Harrigan PR, Gotte M. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′- deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem. 2008 Aug 8; 283 (32): 22222-32.
19. von Wyl V, Ehteshami M, Symons J, Burgisser P, Nijhuis M, Demeter LM, Yerly S, Boni J, Klimkait T, Schuurman R, Ledergerber B, Gotte M, Gunthard HF. Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIV-1 Reverse Transcriptase. J Infect Dis. 2010 Apr 1; 201 (7): 1054-1062.
20. Radzio J, Yap SH, Tachedjian G, Sluis-Cremer N. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. Aids. 2010 Mar; 24(5): 659-67.
21. Poveda E, de Mendoza C, Pattery T, Gonzalez Mdel M, Villacian J, Soriano V. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. Aids. 2008 Nov 12; 22 (17): 2395-8.
22. Julias JG, McWilliams MJ, Sarafianos SG, Arnold E, Hughes SH. Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo. Proc Natl Acad Sci U S A. 2002 Jul 9; 99 (14): 9515-20. (Pubitemid 34764645)
23. Arion D, Sluis-Cremer N, Min KL, Abram ME, Fletcher RS, Parniak MA. Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones. J Biol Chem. 2002 Jan 11; 277 (2): 1370-4. (Pubitemid 34968892)
24. Tisdale M, Schulze T, Larder BA, Moelling K. Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. J Gen Virol. 1991 Jan; 72: 59-66.
25. Cristofaro JV, Rausch JW, Le Grice SF, DeStefano JJ. Mutations in the ribonuclease H active site of HIV-RT reveal a role for this site in stabilizing enzyme-primer-template binding. Biochemistry. 2002 Sep 10; 41 (36): 10968-75.
26. Volkmann S, Wohrl BM, Tisdale M, Moelling K. Enzymatic analysis of two HIV-1 reverse transcriptase mutants with mutations in carboxyl-terminal amino acid residues conserved among retroviral ribonucleases H. J Biol Chem. 1993 Feb 5; 268 (4): 2674-83. (Pubitemid 23057895)
27. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature. 1993 Oct 14; 365 (6447): 671-3.
28. Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ. Combinations of Mutations in the Connection Domain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Assessing the Impact on Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitor Resistance. Antimicrob Agents Chemother. 2010 May; 54(5): 1973-80.